Soda Mbaye, Aïssatou Aw, El Hadji Malick Sy, Aly Mbara Ka, Jean Pierre Diagne, Hawo Madina Diallo, Audrey Samra, Papa Amadou Ndiaye
{"title":"ASSESSMENT OF ARTIFICIAL INTELLIGENCE SOFTWARE FOR AUTOMATIC SCREENING OF DIABETIC RETINOPATHY BASED ON FUNDUS PHOTOGRAPHS IN MELANODERM SUBJECTS.","authors":"Soda Mbaye, Aïssatou Aw, El Hadji Malick Sy, Aly Mbara Ka, Jean Pierre Diagne, Hawo Madina Diallo, Audrey Samra, Papa Amadou Ndiaye","doi":"10.1097/IAE.0000000000004310","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To assess the Gaiha Prio Retino +™ Artificial Intelligence (AI) software for detecting diabetic retinopathy (DR).</p><p><strong>Methods: </strong>This prospective study was conducted from March 1, 2021, to September 30, 2022, in the Ophthalmology Department of the Abass NDAO Hospital (Dakar, Senegal). The clinical classification of DR was based on American Academy of Ophthalmology. The clinical results were compared with those obtained from the automated reading of retinophotos taken using Gaiha Prio Retino +™, a software designed to detect DR.</p><p><strong>Results: </strong>The study covered 305 eyes. Referable DR was observed in 104 eyes by the ophthalmologist and in 96 eyes by AI, corresponding with a sensitivity of 92.31%, a specificity of 99%, and an area under the curve of 0.989. Vision-threatening DR was detected in 102 eyes by the ophthalmologist and in 94 eyes by AI, with a corresponding sensitivity of 92.16%, specificity of 99.01%, and an area under the curve of 0.975. Maculopathy was identified in 93 eyes by the ophthalmologist and in 89 eyes by AI, with a corresponding sensitivity of 95.7%, specificity of 97.17%, and an area under the curve of 0.988.</p><p><strong>Conclusion: </strong>Considering these results, the authors may conclude that Gaiha Prio Retino +™ is an effective tool for screening referable DR.</p>","PeriodicalId":54486,"journal":{"name":"Retina-The Journal of Retinal and Vitreous Diseases","volume":" ","pages":"330-334"},"PeriodicalIF":2.1000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Retina-The Journal of Retinal and Vitreous Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/IAE.0000000000004310","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: To assess the Gaiha Prio Retino +™ Artificial Intelligence (AI) software for detecting diabetic retinopathy (DR).
Methods: This prospective study was conducted from March 1, 2021, to September 30, 2022, in the Ophthalmology Department of the Abass NDAO Hospital (Dakar, Senegal). The clinical classification of DR was based on American Academy of Ophthalmology. The clinical results were compared with those obtained from the automated reading of retinophotos taken using Gaiha Prio Retino +™, a software designed to detect DR.
Results: The study covered 305 eyes. Referable DR was observed in 104 eyes by the ophthalmologist and in 96 eyes by AI, corresponding with a sensitivity of 92.31%, a specificity of 99%, and an area under the curve of 0.989. Vision-threatening DR was detected in 102 eyes by the ophthalmologist and in 94 eyes by AI, with a corresponding sensitivity of 92.16%, specificity of 99.01%, and an area under the curve of 0.975. Maculopathy was identified in 93 eyes by the ophthalmologist and in 89 eyes by AI, with a corresponding sensitivity of 95.7%, specificity of 97.17%, and an area under the curve of 0.988.
Conclusion: Considering these results, the authors may conclude that Gaiha Prio Retino +™ is an effective tool for screening referable DR.
期刊介绍:
RETINA® focuses exclusively on the growing specialty of vitreoretinal disorders. The Journal provides current information on diagnostic and therapeutic techniques. Its highly specialized and informative, peer-reviewed articles are easily applicable to clinical practice.
In addition to regular reports from clinical and basic science investigators, RETINA® publishes special features including periodic review articles on pertinent topics, special articles dealing with surgical and other therapeutic techniques, and abstract cards. Issues are abundantly illustrated in vivid full color.
Published 12 times per year, RETINA® is truly a “must have” publication for anyone connected to this field.